Illumina Ventures Announces Expansion of its Europe Team
Illumina Ventures, an independently-managed, healthcare-focused venture firm in a strategic partnership with Illumina (NASDAQ: ILMN) today announced the addition of four new members to its European team. Arnaud Autret, PhD, MSc, will be Principal and Head of European Operations, William Byrne, PhD, be an Associate – Europe, and Ronan Byrne and Ivan Coulter, PhD, BSc, will serve as Venture Advisors – Europe.
“We are already supporting some great companies in Ireland, France and the UK. The addition of Arnaud, William, Ronan and Ivan to our team will enable us build upon our successes and pursue even more ambitious genomics-focused projects in Europe,” said Nick Naclerio, PhD, Illumina Ventures Founding Partner.
Arnaud brings more than 15 years of financial and investment experience in the life sciences and biopharmaceutical industries, as well as scientific knowledge, to his new position. Before joining the Company, Arnaud was Investment Director in the biotechnology team of M Ventures in Amsterdam, which is the corporate venture capital arm of Merck KGaA. Previously, he worked as the Senior Associate in the Life Sciences team at Seventure Partners in Paris, as well as a senior financial auditor in the healthcare business unit at KPMG, also in Paris. Arnaud completed his post-doctoral work in oncology at the Trinity College Dublin after receiving his PhD in immunology from the Pasteur Institute in Paris. Arnaud also holds a MSc in finance from ESCP Business School, in Paris. Arnaud is based in Amsterdam.
Before joining Illumina Ventures, William was Head of Biotechnology at NEOM, a futuristic megacity that will be located in Saudi Arabia and rely on renewable energy and new technology for sustainable living. William led the efforts to establish NEOM as a global biotech hub with a focus on precision medicine. Previously, he worked as a consultant in the healthcare and life sciences industries providing clients located in the Middle East and Europe with investment, research, go-to-market and product launch strategies. William earned a PhD in tumor immunology and a Bachelor of Pharmacy degree at University College Cork in Ireland. He also holds a Master of Business Administration degree from INSEAD in France. William is based in Cork.
As a highly experienced CEO, Ronan has built and led several companies over his career that he later sold to multinational companies. Over the last decade, he has focused his efforts on the commercialization of innovations in the life sciences industry. He was CEO of ClearSight Innovations (Ophthalmic Diagnostic technologies) which sold to an industry leader and is currently the CEO and Co-founder of Pharma Latch in Dublin, which is developing a revolutionary intradermal delivery technology for drugs, vaccines, and a range of immunotherapies; he is also Business Mentor at Enterprise Ireland. Ronan received both a Master of Business Administration degree and a BA in Economics and Politics from University College Dublin.
Ivan is an entrepreneur with experience in translating early-stage innovations into clinical development programs. As a pharmacologist, he understands the importance of aligning molecular pathways with appropriate therapeutics and diagnostics. He is currently Founder and Managing Director of Eden BioPharma Limited in Dublin. Ivan was also Founder and CEO of Sigmoid Pharma Limited, where he focused on the development of an integrated drug delivery platform within the gastrointestinal tract. As a consultant, he has advised academics and entrepreneurs in setting up companies, developing fundable strategies and building multidisciplinary teams. Ivan obtained his MBA from the Johnson Graduate School of Management at Cornell University in New York and completed his post-doctoral fellowship in developmental biology at the Institut Curie in Paris after receiving a PhD in cancer research and BSc in pharmacology from University College Dublin. He and Ronan are based in Dublin.
“We are committed to supporting new and existing early-stage startups in Europe that are developing innovative clinical diagnostics and life science research tools, as well as therapeutic platforms, digital health initiatives and genomics applications,” said Wouter Meuleman, PhD, Illumina Ventures Partner. “We are excited to have Arnaud, William, Ronan and Ivan join in our efforts.”
About Illumina Ventures
Illumina Ventures is an independently managed, healthcare-focused venture firm in a strategic partnership with Illumina, with the vision to unlock the power of the genome. As an early-stage, value-add investor, Illumina Ventures helps entrepreneurs develop breakthrough science and technologies into market-leading companies to transform healthcare. The firm focuses on investment in life science tools, therapeutics, diagnostics, and personal wellness.
For more information, visit illuminaventures.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005179/en/
Contact information
Valerie Enes, Vice President, Seismic
408-497-8568
valerie@teamseismic.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo